Cargando…
Do Hungarian multiple sclerosis care units fulfil international criteria?
A PATIENTS: Because of the past 3 decades’ extensive research, several disease modifying therapies became available, thus a paradigm change is multiple sclerosis care was necessary. In 2018 a therapeutic guideline was created recommending that treatment of persons with multiple sclerosis should take...
Autores principales: | Kokas, Zsófia, Sandi, Dániel, Fricska-Nagy, Zsanett, Füvesi, Judit, Biernacki, Tamás, Köves, Ágnes, Fazekas, Ferenc, Birkás, Adrienne Jóri, Katona, Gabriella, Kovács, Krisztina, Milanovich, Dániel, Dobos, Enikő, Kapás, István, Jakab, Gábor, Csépány, Tünde, Bense, Erzsébet, Mátyás, Klotild, Rum, Gábor, Szolnoki, Zoltán, Deme, István, Jobbágy, Zita, Kriston, Dávid, Gerócs, Zsuzsanna, Diószeghy, Péter, Bors, László, Varga, Adrián, Kerényi, Levente, Molnár, Gabriella, Kristóf, Piroska, Nagy, Zsuzsanna Ágnes, Sátori, Mária, Imre, Piroska, Péntek, Szilvia, Klivényi, Péter, Kincses, Zsigmond Tamás, Vécsei, László, Bencsik, Krisztina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893632/ https://www.ncbi.nlm.nih.gov/pubmed/35239686 http://dx.doi.org/10.1371/journal.pone.0264328 |
Ejemplares similares
-
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2022) -
Epidemiology of multiple sclerosis in Central Europe, update from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2020) -
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations
por: Biernacki, Tamás, et al.
Publicado: (2022) -
Contributing factors to health‐related quality of life in multiple sclerosis
por: Biernacki, Tamás, et al.
Publicado: (2019) -
Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study
por: Bencsik, Krisztina, et al.
Publicado: (2022)